Literature DB >> 12637336

LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients.

Sung-Joon Lee1, Hannia Campos, Lemuel A Moye, Frank M Sacks.   

Abstract

OBJECTIVE: Triglyceride-rich lipoproteins that contain apolipoprotein CIII (apoCIII) are prominent in diabetic dyslipidemia. We hypothesized that these lipoproteins increase coronary disease risk in diabetic patients beyond that caused by standard lipid risk factors. METHODS AND
RESULTS: Diabetic patients with previous myocardial infarction were followed for 5 years, and 121 who had a recurrent coronary event were matched to 121 who did not. VLDL and LDL that contained or did not contain apoCIII (CIII+ or CIII-) were prepared by immunoaffinity chromatography and ultracentrifugation. IDL was included in the LDL fraction. LDL CIII+, rich in cholesterol and triglyceride, was the strongest predictor of coronary events (relative risk [RR] 6.6, P<0.0001, for 4th versus 1st quartile). LDL CIII+ comprised 10% of total LDL. The main type of LDL, LDL CIII-, was less strongly predictive (RR 2.2, P=0.07). The increased risk associated with LDL CIII+ was unaffected by adjustment for plasma lipids, apoB, non-HDL cholesterol, or the other VLDL and LDL types. For VLDL CIII+, RR 0.5, P=0.07; for VLDL CIII-, RR 2.3, P=0.046. The presence of apolipoprotein E with CIII on VLDL and LDL did not affect risk.
CONCLUSIONS: LDL with apoCIII strongly predicts coronary events in diabetic patients independently of other lipids and may be an atherogenic remnant of triglyceride-rich VLDL metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12637336     DOI: 10.1161/01.ATV.0000066131.01313.EB

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  60 in total

1.  Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial.

Authors:  Jeremy D Furtado; Hannia Campos; Anne E Sumner; Lawrence J Appel; Vincent J Carey; Frank M Sacks
Journal:  Am J Clin Nutr       Date:  2010-09-08       Impact factor: 7.045

2.  Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins.

Authors:  Jeremy D Furtado; Mark K Wedel; Frank M Sacks
Journal:  J Lipid Res       Date:  2012-02-02       Impact factor: 5.922

Review 3.  Diabetic dyslipidemia and cardiovascular risk.

Authors:  Robert H Eckel
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

Review 4.  How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?

Authors:  Francine K Welty
Journal:  Curr Cardiol Rep       Date:  2013-09       Impact factor: 2.931

5.  Using primary murine intestinal enteroids to study dietary TAG absorption, lipoprotein synthesis, and the role of apoC-III in the intestine.

Authors:  Javeed Jattan; Cayla Rodia; Diana Li; Adama Diakhate; Hongli Dong; Amy Bataille; Noah F Shroyer; Alison B Kohan
Journal:  J Lipid Res       Date:  2017-02-03       Impact factor: 5.922

6.  Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Sarah A Aroner; Jeremy D Furtado; Frank M Sacks; Michael Y Tsai; Kenneth J Mukamal; Robyn L McClelland; Majken K Jensen
Journal:  Diabetologia       Date:  2019-04-04       Impact factor: 10.122

7.  Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease.

Authors:  Carlos O Mendivil; Eric B Rimm; Jeremy Furtado; Stephanie E Chiuve; Frank M Sacks
Journal:  Circulation       Date:  2011-10-10       Impact factor: 29.690

8.  Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

Authors:  Dick C Chan; Gerald F Watts; Esther M M Ooi; Juying Ji; Anthony G Johnson; P Hugh R Barrett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-19       Impact factor: 8.311

9.  Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.

Authors:  Eliete J B Bighetti; Patrícia R Patrício; Andrea C Casquero; Jairo A Berti; Helena C F Oliveira
Journal:  Lipids Health Dis       Date:  2009-11-23       Impact factor: 3.876

10.  ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

Authors:  Anne Hiukka; Marcus Ståhlman; Camilla Pettersson; Malin Levin; Martin Adiels; Susanne Teneberg; Eeva S Leinonen; Lillemor Mattsson Hultén; Olov Wiklund; Matej Oresic; Sven-Olof Olofsson; Marja-Riitta Taskinen; Kim Ekroos; Jan Borén
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.